First Quadrant’s Teva Pharmaceuticals TEVA Stock Holding History

First Quadrant’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,776	Closed	-$34K	–	829
2020 Q1	$34K	Sell	3,776 -626	-14%	-$6.41K	﹤0.01%	559
2019 Q4	$43K	Buy	4,402 +626	+17%	+$5.59K	﹤0.01%	521
2019 Q3	$26K	Hold	3,776	–	–	﹤0.01%	561
2019 Q2	$35K	Hold	3,776	–	–	﹤0.01%	654
2019 Q1	$59K	Buy	3,776 +197	+6%	+$3.47K	﹤0.01%	631
2018 Q4	$55K	Hold	3,579	–	–	﹤0.01%	721
2018 Q3	$77K	Hold	3,579	–	–	﹤0.01%	744
2018 Q2	$87K	Buy	+3,579	New	+$73K	﹤0.01%	664
2015 Q1	–	Sell	-463	Closed	-$27K	–	786
2014 Q4	$27K	Hold	463	–	–	﹤0.01%	695
2014 Q3	$25K	Hold	463	–	–	﹤0.01%	735
2014 Q2	$24K	Hold	463	–	–	﹤0.01%	747
2014 Q1	$24K	Hold	463	–	–	﹤0.01%	684
2013 Q4	$19K	Buy	463 +38	+9%	+$1.5K	﹤0.01%	727
2013 Q3	$16K	Hold	425	–	–	﹤0.01%	739
2013 Q2	$17K	Buy	+425	New	+$16.6K	﹤0.01%	741

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Quadrant's TEVA Position: Q2 2020 in Review

First Quadrant sold out of Teva Pharmaceuticals (TEVA) in Q2 2020, closing a stake of 3,776 shares — an estimated $34K sold.

First Quadrant first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $87K in Q2 2018. 455 funds tracked by Wall St. Rank hold TEVA as of Q2 2020.

First Quadrant reported no remaining Teva Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
First Quadrant sold 3,776 Teva Pharmaceuticals shares in Q2 2020, an estimated $34K.
First Quadrant first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
First Quadrant's Teva Pharmaceuticals position peaked at $87K in Q2 2018.
455 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2020.

Based on First Quadrant's 13F filing for Q2 2020, filed 28 Jul 2020.